{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:39Z","timestamp":1761896199659,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clml.2015.10.005","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T18:07:34Z","timestamp":1446660454000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-2382","authenticated-orcid":false,"given":"Arjun","family":"Lakshman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savita","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.10.005_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2015.10.005_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients","volume":"34","author":"Corso","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.10.005_bib3","first-page":"3528","article-title":"Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma\u2014efficacy and neurotoxicity","volume":"108","author":"Borrello","year":"2006","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.clml.2015.10.005_bib4","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.10.005_bib5","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3109\/10428194.2011.598253","article-title":"Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis","volume":"52","author":"Malhotra","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.10.005_bib6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.10.005_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.10.005_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study: reversibility of PN with VMP in newly diagnosed MM","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.10.005_bib9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1398::AID-MUS6>3.0.CO;2-4","article-title":"Body mass index effect on common nerve conduction study measurements","volume":"21","author":"Buschbacher","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clml.2015.10.005_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1085-9489.2005.00047.x","article-title":"Obesity and peripheral neuropathy risk: a dangerous liaison","volume":"10","author":"Miscio","year":"2005","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.clml.2015.10.005_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/mus.1136","article-title":"Painful sensory polyneuropathy associated with impaired glucose tolerance","volume":"24","author":"Singleton","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clml.2015.10.005_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/mus.20785","article-title":"Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms","volume":"36","author":"Zochodne","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clml.2015.10.005_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.10.005_bib14","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"Classification and diagnosis of diabetes","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clml.2015.10.005_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-2005-871330","article-title":"Chronic inflammatory demyelinating polyneuropathy and other immune-mediated demyelinating neuropathies","volume":"25","author":"Lewis","year":"2005","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clml.2015.10.005_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.clml.2015.10.005_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199507133330203","article-title":"Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"Partanen","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.10.005_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/dc09-1694","article-title":"A1C cut points to define various glucose intolerance groups in Asian Indians","volume":"33","author":"Mohan","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clml.2015.10.005_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pcd.2011.02.002","article-title":"HbA1c values for defining diabetes and impaired fasting glucose in Asian Indians","volume":"5","author":"Nair","year":"2011","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clml.2015.10.005_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.10.005_bib21","first-page":"163","article-title":"Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management","volume":"57","author":"Misra","year":"2009","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.clml.2015.10.005_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.20713","article-title":"Uremic neuropathy: clinical features and new pathophysiological insights","volume":"35","author":"Krishnan","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clml.2015.10.005_bib23","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.10.005_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in multiple myeloma treated with thalidomide: a prospective study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clml.2015.10.005_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.clml.2015.10.005_bib26","first-page":"11","article-title":"Multiple myeloma: recent advances","volume":"19","author":"Kumar","year":"2001","journal-title":"Indian J Hematol Blood Transf"},{"key":"10.1016\/j.clml.2015.10.005_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1385\/MO:19:3:141","article-title":"Lympho-hemopoietic malignancies in India","volume":"19","author":"Bhutani","year":"2002","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2015.10.005_bib28","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-012-1491-5","article-title":"B\u00a0cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center","volume":"91","author":"Prakash","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.10.005_bib29","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015013373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T21:30:23Z","timestamp":1537219823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015013373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S2152265015013373"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.10.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}